Glenmark Pharma Cash flow Statement
Figures in Cr
Consolidated Cash Flow Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
No of Months
12
12
12
12
12
12
Profit Before Tax
1,399.00
569.00
868.00
1,441.00
1,382.00
1,096.00
Adjustment
982.00
1,009.00
1,471.00
787.00
644.00
636.00
Changes In working Capital
-2,528.00
-796.00
-1,074.00
-561.00
-385.00
127.00
Cash Flow after changes in Working Capital
-147.00
782.00
1,265.00
1,667.00
1,641.00
1,859.00
Cash Flow from Operating Activities
-827.00
-265.00
625.00
1,108.00
1,131.00
1,392.00
Cash Flow from Investing Activities
57.00
4,386.00
-515.00
-315.00
-661.00
-773.00
Cash Flow from Financing Activities
787.00
-3,906.00
-77.00
-520.00
-441.00
-444.00
Net Cash Inflow / Outflow
17.00
215.00
32.00
272.00
27.00
174.00
Opening Cash & Cash Equivalents
1,658.00
1,443.00
1,410.00
1,138.00
1,110.00
936.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
1,675.00
1,658.00
1,443.00
1,410.00
1,138.00
1,110.00
Figures in INR Cr
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Glenmark Pharma
Figures in Cr
standaloned Cash Flow Results
Change(INR)
Change(%)
Profit Before Tax
2154.02
1886.95
268.00
14.15%
Adjustment
154.2
-164.63
318.00
193.66%
Changes In working Capital
-1136.55
-263.42
-873.00
-331.46%
Cash Flow after changes in Working Capital
1171.67
1458.9
-287.00
-19.69%
Cash Flow from Operating Activities
588.8
1011.84
-423.00
-41.81%
Cash Flow from Investing Activities
-489.9
182.18
-671.00
-368.91%
Cash Flow from Financing Activities
-95.41
-925.17
830.00
89.69%
Net Cash Inflow / Outflow
3.49
268.85
-265.00
-98.70%
Opening Cash & Cash Equivalents
127.96
291.74
-164.00
-56.14%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
0
0.00
0.00%
Closing Cash & Cash Equivalent
131.45
560.59
-429.00
-76.55%
Cash Flow - Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is -211.78% vs -142.44% in Mar 2024
Mar'25
Mar'24
Change(%)
Cash Flow from Operating Activities
-827.60
-265.44
-211.78%






